Drugs / QBKPN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05421325 | Apr 2023 → Sep 2025 overdue | immunodeficiency disease | Qu Biologics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-07-20 | Qu Biologics Inc. | Regulatory Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead qubiologics.com ↗
With the receipt of Health Canada’s No Objection Letter, the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) has committed additional advisory services and conditional funding to support this important clinical study. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-07-20 | Qu Biologics Inc. | Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead qubiologics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBKPN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05421325 ↗ |
| Route | Subcutaneous | “by subcutaneous injection” NCT05421325 ↗ |